Healthcare Sector

The net profit and EBITDA margin excluding ex-Cenexi, a contract manufacturing firm that Gland acquired for more than ₹1,000 Crore last year.

This approval builds on company’s successful track record of bringing the first interchangeable insulin, Semglee.

Lupin said the business is thoroughly reviewing the findings and would respond to the USFDA within the timeframe specified.

During the quarter, Mankind introduced four new drugs in the United States, bringing the total number of launched items to 39.

The partnership follows Biocon's success in becoming the first business to receive approval for gLiraglutide in an ICH country.

Profit before tax was lower in Q4 FY2024 due to an impairment charge of ₹201.3 Crore. The quarter's R&D investment totaled ₹425.5 Crore (8.7% of revenue).

With the acquisition of Medica, Manipal facilities now serve 7 million patients yearly across 37 facilities in 19 cities throughout 14 states.

Biomm's Nova Lima production facility is dedicated to the development, manufacture, and commercialization of complex biotech and biosimilar medicinal products.

In terms of imminent development in Uttar Pradesh, he stated that the business is looking to expand by another 300-odd beds going forward.

The company's board has decided not to declare an interim dividend for fiscal year 2023-24.